Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
GSTP1 protein level is very low in human breast cancer cell line MCF-7 but is high in ADR-resistant MCF-7/ADR cells.
|
30683915 |
2019 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
The correlation between HER2 and Ki67/GSTP1 and clinical/pathological features of BC was analyzed.
|
30585764 |
2019 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Four hypermethylated alleles (RARβ2, BRCA1, GSTP1 and RASSF1A) related to breast cancer in twenty-three clinical samples were tested using the microwell chip dPCR-based MethyLight assay.
|
29693662 |
2018 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Individuals with homozygous variant genotypes for GSTP1 or COMT exhibited a higher risk of developing breast cancer than those with wild-type genotypes; however, for CYP1B1, the homozygous variant genotype was associated with a lower risk, and the heterozygous genotype for these 3 genes was not associated with breast cancer development.An individual's risk of breast cancer is only influenced by the specific combination of risk-associated alleles of COMT and GSTP1, despite the protective effects of the homozygous CYP1B1 genotype revealed by univariate analysis.
|
30461653 |
2018 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Then lv-GSTP1 and GSTP1-shRNA plasmids were constructed to investigate the potential of GSTP1 in regulating chemoresistance of breast cancer.
|
29116019 |
2017 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated whether GSTT1 ("null" allele), GSTM1 ("null"allele), GSTP1 (A313G), RFC1 (G80A), MTHFR (C677T), TS (2R/3R) polymorphisms were associated with toxicity and survival in patients with early breast cancer (EBC) treated with adjuvant chemotherapy (CT).
|
28747156 |
2017 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Previous studies have identified GSTP1 as a predictor of prognosis and chemo-resistance in breast cancer patients, but the mechanisms governing GSTP1-dependent drug resistance are still unclear.
|
28438694 |
2017 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggest that wild-type GSTP1 or CYP17 genes when combined with LOH/MSI in steroid metabolism genes may play a role in ER and/or PR negative breast cancers.
|
28692125 |
2017 |
Malignant neoplasm of breast
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
However, quantitation of methylation confirmed a hypermethylated phenotype at CDH1 and GSTP1 promoters as well as a differential methylation pattern at DNMT3B promoter in breast cancer.
|
28979331 |
2017 |
Malignant neoplasm of breast
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Epigenetic silencing of glutathione S-transferase pi 1, a tumor suppressor gene, is involved in various types of cancers including breast cancer.
|
28222671 |
2017 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Increasing adherence to the MD reduced BC risk in women with at least one GSTP1 Ile allele (OR for Ile/Ile = 0.84, 95 % CI 0.74-0.95, for Ile/Val = 0.73, 95 % CI 0.62-0.85) or one NAT2 590G allele (OR for 590 GG = 0.73, 95 % CI 0.63-0.83, for 590 GA = 0.81, 95 % CI 0.70-0.94). p interaction values were not, however, statistically significant.
|
26572891 |
2017 |
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry was used to detect GSTP1 expression in breast cancer tissue from 175 patients.
|
28978147 |
2017 |
Malignant neoplasm of breast
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Our study is the first of its kind in Kashmiri population, which indicates that GSTP1 shows aberrant methylation pattern in the breast cancer with the consequent loss in the protein expression.
|
28443466 |
2017 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our data demonstrate that these ESR1, GSTP1, and CYP19 polymorphisms are associated with risk of BC, and the risk haplotype TGGGGTC could help to identify populations with high susceptibility to BC in Chinese women.
|
27323034 |
2016 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study was undertaken to evaluate the association between GSTM1, GSTT1 and GSTP1 gene polymorphism and breast cancer risk in Mizoram population.
|
26407578 |
2016 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CYP1A1 and GSTP1 gene variations in breast cancer: a systematic review and case-control study.
|
26545608 |
2016 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The meta-analysis indicated that the GSTP1 rs1695 A>G polymorphism did not contribute to the susceptibility of BC when the overall population was considered.
|
27323180 |
2016 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
And the heterogeneity present in different studies, evaluating the association of GSTP1 polymorphism with response to anthracycline-based chemotherapy, disappeared in breast cancer patients after subgroup analysis by chemotherapy regimen was performed.
|
27785604 |
2016 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study retrospectively explored pharmacogenetic associations of single nucleotide polymorphisms (SNPs) of the uridine glucuronosyltransferase 2B7 (UGT2B7, rs7668258), glutathione-S-transferase pi 1 (GSTP1, rs1695), and microcephalin 1 (MCPH1, rs2916733) genes with chemotherapy-related adverse events in 102 Japanese women who received epirubicin and cyclophosphamide as perioperative chemotherapy for early breast cancer.
|
25008867 |
2016 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphism of GSTP1 IIe105Val might affect the clinical outcome in breast cancer patients.
|
25773389 |
2015 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in GSTM1, GSTP1, and GSTO1 enzymes increase the risk of developing breast cancer and hepatocellular carcinoma.
|
26682223 |
2015 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Data from this study suggest that increased hypermethylation of GSTP1, ID4, TWIST, DAPK, PAX5 and HIN-1 genes in TNBC than in non-TNBC can act as useful biomarker for BCs in the Saudi population.
|
25684485 |
2015 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study was to determine the frequencies of polymorphisms in the genes GSTM1, GSTT1, GSTP1, and GSTM3 and to investigate whether an association exists between these genes and breast cancer risk in subjects from northeastern Mexico.
|
26125851 |
2015 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thus, our findings provided statistical evidence that the variants of GSTP1 and GSTM1 polymorphisms could influence the response to chemotherapy and overall survival in breast cancer patients treated with chemotherapy.
|
26345960 |
2015 |
Malignant neoplasm of breast
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Overall, the pooled results indicated that aberrant GSTP1 promoter methylation was significantly associated with the risk of breast cancer (OR = 7.85, 95 % CI = 5.12-12.01; Caucasians OR = 7.23, 95 % CI = 3.76-13.90 and Asians OR = 11.71, 95 % CI = 5.69-24.07).
|
26585467 |
2015 |